Global Orally Disintegrating Tablet Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.
Global Orally Disintegrating Tablet main manufactuers include Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb and Conquer, totally accounting for about 17% of the market. North America is the largest market of glass packaging, holding a share more than 40%. As for the types of products, it can be divided into anti-psychotics drug, anti-epileptics drug and others. As for the applications of products, it is widely used in CNS diseases, gastrointestinal diseases, CVS diseases and others. The most common application is in CNS diseases packaging, with a share about 55%.

Market Analysis and Insights: Global Orally Disintegrating Tablet Market
In 2020, the global Orally Disintegrating Tablet market size was US$ 12390 million and it is expected to reach US$ 27000 million by the end of 2027, with a CAGR of 11.7% during 2021-2027.
Global Orally Disintegrating Tablet Scope and Market Size
Orally Disintegrating Tablet market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Orally Disintegrating Tablet market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2016-2027.

Segment by Type, the Orally Disintegrating Tablet market is segmented into
Anti-Psychotics Drug
Anti-Epileptics Drug
Others

Segment by Application, the Orally Disintegrating Tablet market is segmented into
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Others

Regional and Country-level Analysis:
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Competitive Landscape

and Orally Disintegrating Tablet Market Share Analysis
Orally Disintegrating Tablet market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2016-2021. Details included are company description, major business, Orally Disintegrating Tablet product introduction, recent developments, Orally Disintegrating Tablet sales by region, type, application and by sales channel.

The major companies include:
Teva
Merck
Mylan
Pfizer
Johnson and Johnson
GSK
Otsuka
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Conquer